Study
| Open-label phase 1–2 trial |
| Previously platinum-based chemotherapy |
| Advanced or metastatic RET fusion positive NSCLC pts who had been treated with platinum (phase I: 49 pts) and who were untreated (phase II: 56 pts) |
| Selpercatinib 160 mg twice daily |
Efficacy
| ORR: 64% (CR:2%, PR:62%, SD:29%) |
| DOR: 17.5 months |
| mPFS: 16.5 months |
Safety
| Any grade AEs: 91%, dry mouth:36%, diarrhea:25%, AST elevation:30% |
| Any grade ≥3 AEs: Hypertension:14%, ALT elevation:13%, hyponatremia: 6%, lymphopenia:6% |
N Engl J Med 2020; 383:813-824
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
http://doi.org/10.1056/NEJMoa2005653
Reviewed by Hasan Cagri Yildirim, MD on Nov 26, 2022
